ACD 101

Drug Profile

ACD 101

Alternative Names: 124I-ACD-101; 131I-ACD-101; ACD-101

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Amino acids; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Apoptosis stimulants; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Glioma

Most Recent Events

  • 19 Jan 2017 Telix Pharmaceuticals enters into a partnership with Therapeia GmbH to acquire ACD 101 theranostic program for glioblastoma
  • 18 Jan 2017 Clinical trials in Glioma in Europe (IV)
  • 04 Mar 2016 ACD 101 is available for licensing -
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top